Search

Displaying results 1691 - 1700 of 3889 in total
  1. Drug

    Salix nigra pollen

    go.drugbank.com/drugs/DB10398
    Approved

    Salix nigra pollen is the pollen of the Salix nigra plant. Salix nigra pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  2. Drug

    Streptococcus pneumoniae type 6a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB16609
    ApprovedInvestigational

    Mixtures: SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (SINGLE DOSE - 1 DOSE), SII PNEUMOSIL Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-Valent) SUSPENSION FOR INJECTION (MULTIDOSE - 5 DOSE)
  3. Drug

    Meradimate

    go.drugbank.com/drugs/DB11096
    Approved

    Meradimate, before known as menthyl anthranilate, is used in a maximal concentration of 5% in different products as a UV filter. It is currently required to be named as meradimate in all FDA approved OTC products. Meradimate is approved ...

  4. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533]

  5. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]

  6. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC). Odevixibat is the first approv...

  7. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.

    Categories: Genito Urinary System and Sex Hormones
  8. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  9. Drug

    Empesertib

    go.drugbank.com/drugs/DB19473
    Investigational

    Empesertib is under investigation in clinical trial NCT02138812 (Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel). … The usage of the INN stem '-sertib' in the name indicates that Empesertib is a serine/threonine kinase inhibitor.

  10. Drug

    Acloproxalap

    go.drugbank.com/drugs/DB21553
    Investigational

    Acloproxalap is under investigation in clinical trial NCT06685692 (A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)).